Switch theme
Sign up to access all valuation multiples
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
1980
5.7K+
LTM Revenue $2.0B
LTM EBITDA $745M
$11.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Qiagen has a last 12-month revenue (LTM) of $2.0B and a last 12-month EBITDA of $745M.
In the most recent fiscal year, Qiagen achieved revenue of $2.0B and an EBITDA of $368M.
Qiagen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Qiagen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $967M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $745M | XXX | $368M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $595M | XXX | $200M | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $502M | XXX | $83.6M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $728M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, Qiagen's stock price is $49.
Qiagen has current market cap of $10.5B, and EV of $11.0B.
See Qiagen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.0B | $10.5B | XXX | XXX | XXX | XXX | $2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, Qiagen has market cap of $10.5B and EV of $11.0B.
Qiagen's trades at 5.5x EV/Revenue multiple, and 29.8x EV/EBITDA.
Equity research analysts estimate Qiagen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Qiagen has a P/E ratio of 21.0x.
See valuation multiples for Qiagen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.5B | XXX | $10.5B | XXX | XXX | XXX |
| EV (current) | $11.0B | XXX | $11.0B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 29.8x | XXX | XXX | XXX |
| EV/EBIT | 18.5x | XXX | 54.9x | XXX | XXX | XXX |
| EV/Gross Profit | 8.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.0x | XXX | 126.0x | XXX | XXX | XXX |
| EV/FCF | 25.0x | XXX | 21.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQiagen's last 12 month revenue growth is 5%
Qiagen's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Qiagen's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Qiagen's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Qiagen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Qiagen acquired XXX companies to date.
Last acquisition by Qiagen was XXXXXXXX, XXXXX XXXXX XXXXXX . Qiagen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Qiagen founded? | Qiagen was founded in 1980. |
| Where is Qiagen headquartered? | Qiagen is headquartered in United States of America. |
| How many employees does Qiagen have? | As of today, Qiagen has 5.7K+ employees. |
| Who is the CEO of Qiagen? | Qiagen's CEO is Mr. Thierry Bernard. |
| Is Qiagen publicy listed? | Yes, Qiagen is a public company listed on NYS. |
| What is the stock symbol of Qiagen? | Qiagen trades under QGEN ticker. |
| When did Qiagen go public? | Qiagen went public in 1996. |
| Who are competitors of Qiagen? | Similar companies to Qiagen include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Qiagen? | Qiagen's current market cap is $10.5B |
| What is the current revenue of Qiagen? | Qiagen's last 12 months revenue is $2.0B. |
| What is the current revenue growth of Qiagen? | Qiagen revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Qiagen? | Current revenue multiple of Qiagen is 5.4x. |
| Is Qiagen profitable? | Yes, Qiagen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Qiagen? | Qiagen's last 12 months EBITDA is $745M. |
| What is Qiagen's EBITDA margin? | Qiagen's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Qiagen? | Current EBITDA multiple of Qiagen is 14.7x. |
| What is the current FCF of Qiagen? | Qiagen's last 12 months FCF is $439M. |
| What is Qiagen's FCF margin? | Qiagen's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Qiagen? | Current FCF multiple of Qiagen is 25.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
